Portal de Periódicos da CAPES

Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B

2005; Lippincott Williams & Wilkins; Volume: 17; Issue: 8 Linguagem: Inglês

10.1097/00042737-200508000-00011

1473-5687

Dariusz Lebensztejn, M Sobaniec‐Lotowska, Michael Bauer, M Kaczmarski, Michael Voelker, Detlef Schuppan,

Hepatitis C virus research

Objective Interferon alfa (IFN-α) may retard hepatic fibrogenesis in adults with chronic hepatitis C. We evaluated prospectively four selected serum fibrosis markers before, immediately after and 12 months after IFN treatment of children with chronic hepatitis B (CHB). Methods Forty-seven children (mean age 8 years, range 4–16) with CHB underwent IFN-α treatment (3 MU t.i.w.) for 5 months. Fibrosis and inflammation were assessed blindly before and 12 months after the end of treatment. Serum laminin-2, collagen IV, MMP-2 and MMP-9/TIMP-1 complex were determined using automated assays. Results Twelve months after treatment had been discontinued levels of laminin-2, collagen IV and MMP-2 were decreased, and serum MMP-9/TIMP-1 complex was increased. Levels did not differ between sustained responders (42.5%) and non-responders. Similarly, fibrosis did not progress in both groups, whereas histological inflammation improved only in responders. Conclusions A 5 month IFN-α treatment has no marked effect on histological liver fibrosis in children with CHB, irrespective of virological response. The evolution of serum fibrosis markers suggests they may be more sensitive to detect minor antifibrotic effects than semiquantitative follow-up histology.